These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1361354)

  • 1. Summary: Clinical Immunology Working Group.
    Zolla-Pazner S; Mathieson BJ; Walker MC; Walker B
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1441-3. PubMed ID: 1361354
    [No Abstract]   [Full Text] [Related]  

  • 2. The importance of standardisation of laboratory evaluations in HIV vaccine trials.
    Gotch F; Holmes H; Imami N
    Microbes Infect; 2005 Nov; 7(14):1424-32. PubMed ID: 16257559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination.
    Locher CP; Grant RM; Collisson EA; Reyes-Terán G; Elbeik T; Kahn JO; Levy JA
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1685-9. PubMed ID: 10606091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen presentation and related immunological aspects of HIV-1 vaccines.
    Steinman RM; Germain RN
    AIDS; 1998; 12 Suppl A():S97-112. PubMed ID: 9632991
    [No Abstract]   [Full Text] [Related]  

  • 6. Conference on advances in AIDS vaccine development--1993. Summary: correlates of HIV Immunity Working Group.
    Sheppard H; Bridges SH; Mathieson BJ; Walker MC; Weinhold K
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S171-6. PubMed ID: 7865294
    [No Abstract]   [Full Text] [Related]  

  • 7. A strategy for prophylactic vaccination against HIV.
    Salk J; Bretscher PA; Salk PL; Clerici M; Shearer GM
    Science; 1993 May; 260(5112):1270-2. PubMed ID: 8098553
    [No Abstract]   [Full Text] [Related]  

  • 8. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design.
    Cagigi A; Nilsson A; De Milito A; Chiodi F
    Vaccine; 2008 Jun; 26(24):3016-25. PubMed ID: 18164520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
    Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
    Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological responses to candidate AIDS vaccines.
    Graham BS
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S145-8. PubMed ID: 7865290
    [No Abstract]   [Full Text] [Related]  

  • 12. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV vaccines: a brief overview.
    Lema D; Garcia A; De Sanctis JB
    Scand J Immunol; 2014 Jul; 80(1):1-11. PubMed ID: 24813074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
    Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
    EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific activation strategies for amplification of low CTL signals.
    Weinhold KJ; Tartaglia J; Paoletti E; Graham B; Schwartz D; McElrath J; Roberts N; Gorse G
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1373. PubMed ID: 1466958
    [No Abstract]   [Full Text] [Related]  

  • 16. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
    Parren PW; Moore JP; Burton DR; Sattentau QJ
    AIDS; 1999; 13 Suppl A():S137-62. PubMed ID: 10885772
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HIV vaccination].
    Jablonowski H
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():68-9. PubMed ID: 19031568
    [No Abstract]   [Full Text] [Related]  

  • 19. HIV/AIDS: allied responses.
    Mascola JR
    Nature; 2007 Sep; 449(7158):29-30. PubMed ID: 17805280
    [No Abstract]   [Full Text] [Related]  

  • 20. AIDS vaccine development.
    Lévy JP
    Science; 1998 May; 280(5365):806-7. PubMed ID: 9599149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.